다운로드 Atrial Fibrillation Patient Decision Tool PC 용

Windows 11에서 모바일 앱을 사용하려면 Amazon Appstore를 설치해야 합니다. 설정이 완료되면 선별된 카탈로그에서 모바일 앱을 검색하고 설치할 수 있습니다. Windows 11에서 Android 앱을 실행하려는 경우 이 가이드가 적합합니다..

1. 컴퓨터가 호환되는지 확인: 최소 요구 사항은 다음과 같습니다.
• RAM: 8GB (최저한의), 16GB (추천)
• 저장: SSD
• Processor:
• Intel Core i3 8th Gen (최소 이상)
• AMD Ryzen 3000 (최소 이상)
• Qualcomm Snapdragon 8c (최소 이상)
• Processor Architecture: x64 or ARM64
2. Atrial Fibrillation Patient Decision Tool 에 이미 기본 Windows 버전이 있는지 확인하십시오. 여기서 하세요 ». 기본 버전이 없으면 3단계로 진행합니다.

The atrial fibrillation patient decision tool is a mobile application created by physicians and pharmacists, designed for patients with atrial fibrillation to choose the most ideal blood thinner agent for their personal preferences and characteristics. Atrial fibrillation is the most common abnormal heart rhythm in the world. The incidence increases with age. Having atrial fibrillation increases the risk of stroke, which can be quite disabling. To prevent stroke in atrial fibrillation, patients need to take blood thinners. However, there are many agents out there with different characteristics including cost and efficacy. How does a patient who is not well versed in the medical field choose one of these agents? Well, traditionally, it would involve a visit to the doctor’s office and a long conversation. However, we think there is a better way. This mobile app allows the clinician to take an interactive, educational application to the bedside or exam room of a patient, and show them the decision making process for choosing an appropriate medication for stroke prevention. It allows the patient to visualize the thought process of prioritizing the factors, including cost, complexity, side effect profile, and efficacy. In the end, the app makes a recommendation to the patient, which is based on data from randomized clinical trials that are well accepted in the medical literature. --------------- Information for health care providers This electronic tool will aim to standardize the discussion process and take into account the patient's preferences such that the patient is empowered in the decision-making process. A literature review was completed using several landmark trials and consensus guidelines on thromboembolic prophylaxis in patients with atrial fibrillation. For the purposes of assessing the patient's stroke and bleed risk, we reviewed the literature supporting use of the HAS-BLED and CHADS2 scoring systems. In developing the algorithm, four main factors were considered: 1. Risk of a stroke or thromboembolic event, as determined by the CHADS2 score. 2. Risk of major or minor bleeding, as determined by the HASBLED score. 3. Patient adherence. 4. Cost. Patients who have renal failure, mechanical heart valves, and various cardiac conditions were excluded from this assessment tool in keeping with the exclusion criteria in the landmark trials. With clinician assistance, this tool should take less than 15 minutes to complete.